Search peptides, terms, sources/
Research source · 2022

0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

About this source

Kind
Research
Design
RCT, Human clinical trial
Population
Human, Stage 2 or 3 neurotrophic keratopathy; 18 subjects in the healing comparison (10 RGN-259, 8 placebo)
Sample size
18
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Very small trial. The complete-healing comparison at 4 weeks (6 of 10 versus 1 of 8) gave p = 0.0656, above the usual 0.05 threshold. Eye drops of full-length thymosin beta-4, not the TB-500 fragment. Verified from the Europe PMC abstract record.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.